Noted during our consultation. I will set up a private, encrypted Proton Drive folder for you and send you the secure upload link directly. Please upload a complete written list there ahead of our next review call. The table below is a working record only.
| Product / Medication | Dose | Timing | Purpose / Client Note | BNH Review Status |
|---|---|---|---|---|
| Ivermectin (human grade) Active | 50mg | Daily | Antiparasitic, prescribed under Invita oncologist following tumour marker blood work. Raised from 12mg to 50mg. Continue as currently prescribed. | Noted, continue per Invita prescriber |
| Reishi extract tincture Supplement | Per Nevada doctor protocol | Daily, ongoing | Long-term immune and metabolic support. Permanent recommendation from Nevada-based doctor. | Continue, complements protocol well |
| Functional mushroom powder Supplement | Per label | Daily | Whole-food fungal support. Ground form retains useful bioactivity. | Continue, upload brand details to Proton Drive folder |
| Functional mushroom capsule Supplement | Per label | Daily | Additional fungal blend supporting immune function. | Continue, upload brand details to Proton Drive folder |
| Astragalus root extract Supplement | Per label, capsule form | Daily | Traditional adaptogen, immune system support. | Continue, upload brand details to Proton Drive folder |
| Beta-glucan yeast product (under review) Pending | Awaiting product details | Not yet started | Nutraceutical product you shared with me by link, undergoing clinical trial attention. Specific beta-glucan combinations (1,3 and 1,6). I will review the literature and respond. | Under review by me, will respond directly |
| Full supplement and medication list Pending | — | — | Please upload a complete written list of all current supplements and medications with doses and timing to your secure Proton Drive folder. | Awaiting your list |
A central part of the Bonner Natural Health consultation is taking the time to understand the fuller context of a client's health journey. Rather than focusing solely on current symptoms, we explore patterns, timelines, lifestyle factors, and personal history together.
Corey, as you know, your diagnosis is uncommon and sits outside the three more familiar sarcoma subtypes. You have done significant work to understand your own disease, you have been an active and informed participant in every step of your care to date, and you are currently in a strong and asymptomatic state despite the imaging findings in the lungs.
You are coming into this protocol from a position of strength: physically capable, mentally engaged, already moving in the right nutritional direction, and willing to commit to the time the protocol needs. The endocannabinoid system operates as a master regulator across all tissue, the metabolic framework proposed by Professor Seyfried applies broadly to disease cell energy demand, and the body's own homeostatic response to consistent multi-cannabinoid support has been observed across a wide range of contexts.
The Bonner Natural Health framework is structured around five interconnected pillars. Corey, you are adopting the first three: the endocannabinoid system, the gut-brain axis, and detox and cleanse. These three pillars sit at the physical and metabolic core of the protocol, and together cover the most direct levers we can pull to support your body's own regulatory intelligence.
Every human produces cannabinoids within the body. The endocannabinoid system plays a significant role in supporting homeostasis and overall balance. Research suggests that as we age, experience stress, or face ongoing health challenges, the body's own cannabinoid production may become less optimal. The ECS has more receptor sites associated with it than any other receptor system in the human body, and it is present throughout peripheral organs, tissue, the brain, and the gut.
Phytocannabinoids from the hemp plant have a molecular structure that closely resembles the cannabinoids the human body produces naturally. Hemp-derived products used in the Bonner Natural Health protocol contain no psychoactive compounds, are derived from the hemp plant (not cannabis), and are fully legal under the 2018 Farm Bill. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
The entourage effect. Research indicates that a broad-spectrum multi-cannabinoid formulation engaging CB1, CB2, TRPV1, and associated receptors may offer broader support than CBD isolate alone. My formulations contain twelve phytocannabinoids working in combination. This is sometimes referred to as the entourage effect in the scientific literature.
Why suppository delivery? Oral supplement absorption can be significantly reduced by first-pass liver metabolism, with estimates suggesting 5 to 15% bioavailability for many oral CBD products. Rectal delivery bypasses this process, with estimated bioavailability of 70 to 90%. The formulation is absorbed through rectal tissue and distributed throughout the body within approximately 15 to 20 minutes.
A significant proportion of immune cells are located in the gut. The microbiome, the quality of gut lining function, and the balance of what we eat and drink are all closely connected to how we feel, how clearly we think, and how well our body maintains its natural balance. Nutrition is one of the most powerful lifestyle levers available to us.
Professor Seyfried is a Professor of Biology at Boston College and one of the leading voices in metabolic health research. His peer-reviewed work, including his widely cited book Cancer as a Metabolic Disease (2012), builds on Nobel laureate Otto Warburg's foundational observations and proposes that many dysfunctional cells share a common metabolic characteristic: a shift away from normal oxidative energy production toward a fermentation-based process fuelled primarily by glucose and glutamine. His published research observes that this shift occurs when mitochondrial function is compromised, and that reducing the availability of fermentable fuels, principally through a calorie-conscious, lower-carbohydrate dietary approach, may support the body's own metabolic balance. These findings are the subject of ongoing peer-reviewed research and preclinical and clinical studies. The Bonner Natural Health nutritional approach draws on this framework as educational context, not as a clinical protocol for any disease.
Dr. Gundry is a former cardiothoracic surgeon and author of The Plant Paradox and The Gut-Brain Paradox. His clinical perspective proposes that lectins, a class of proteins found in many plants, grains, and legumes, may disrupt the gut lining, contribute to systemic inflammation, and impair immune function in some individuals. He advocates for a dietary approach that reduces lectin-containing foods as a means of supporting gut integrity and reducing inflammatory burden. His views remain a subject of active discussion within the nutrition and medical community, and his work is one of several perspectives that informs the Bonner Natural Health nutritional framework. Clients with specific health conditions should discuss any significant dietary changes with their healthcare team.
Beta-glucan product under evaluation. You have shared a link with me to a beta-glucan yeast nutraceutical product (1,3 and 1,6 beta-glucan combinations) currently undergoing clinical trial attention from Merck for cancers metastasised to the liver. The product has been in long-term use by your contact for over twenty years. I will review the literature and respond to you directly.
The body has its own sophisticated detoxification systems, primarily the liver, kidneys, lymphatic system, and gut. Supporting these systems through hydration, nutrition, and appropriate supplementation helps the body maintain its natural cleansing functions more effectively. The phytocannabinoid protocol, alongside the nutrition guidance, is designed to work with and support these existing processes.
Supporting natural detoxification. Adequate hydration is one of the most impactful ways to support liver and kidney function. Combining quality hydration with a whole-food, lower-toxin diet reduces the burden on these systems. The phytocannabinoid formulations are distributed broadly throughout the body and may support the body's own regulatory and balancing functions over time.
Layering with existing antiparasitic care. You are already on ivermectin at 50mg daily under your Invita oncologist. My formulation's own antimicrobial and antiparasitic properties layer on top of this, complementing your existing care. Fenbendazole context and the educational references I will send through are flagged in Section 02 and Section 04. Binding agents such as zeolite, activated charcoal, and berberine tincture are available over the counter and are not medications. They can support the body's natural cleansing if any adjustment symptoms arise. We discussed the Herxheimer reaction: as the formulation works through your system, some clients experience a temporary die-off response. This can feel headachy for four or five days. If this happens to you, contact me promptly. Do not adjust any prescribed medication in response. Consult a healthcare professional if anything feels concerning.
A clear record of what we agreed during the consultation. We both have actions. Use this as your reference.
Corey, the following is the scientific rationale for what the protocol is doing inside your body. It is drawn from the published literature on rhabdomyosarcoma, on soft tissue sarcoma broadly, and on the basic biology of the endocannabinoid system. The reference papers are linked throughout so you can read them yourself or share them with your Invita team.
Your endocannabinoid system, the ECS, is a regulatory network that runs throughout your body. It is built around two main receptors, CB1 and CB2, that sit on the surface of your cells. CB1 is concentrated in the nervous system and in skeletal muscle. CB2 is concentrated on immune cells, particularly on macrophages, which are the same cell type that makes up the dense inflammatory infiltrate in your tumour. The ECS also signals through several other pathways, including PPAR receptors, TRP channels, and a set of enzymes that govern inflammation, including COX-2.
The ECS is, in plain terms, the body's master regulator of balance. It governs inflammation, cell growth, cell death, immune behaviour, pain signalling, and tissue repair. When it is operating well, the body has a much stronger capacity to regulate the conditions that allow disease to either progress or quiet down. When it is underactive, the body loses that regulatory leverage. The work of the formulations is to bring your ECS up to full operating capacity and then to keep it there for a sustained period, because that is when the system can do meaningful work for you.
For inflammatory rhabdomyoblastic tumour specifically, several features of the disease make ECS activation a relevant therapeutic angle. The most important of these are set out below.
This is the most striking finding for your situation. Research from the University of Zurich performed gene expression profiling on rhabdomyosarcoma tumour biopsies and found that the gene coding for the CB1 cannabinoid receptor is highly upregulated in these tumours. They then showed that activating CB1 in these cells with cannabinoid agonists lowers tumour cell viability through a process called apoptosis, which is the body's mechanism of programmed cell death, the orderly removal of cells that should no longer be there. The mechanism worked through inhibition of the PI3K/Akt survival pathway, which is one of the central pathways tumour cells use to resist dying.
A separate study in a human skeletal muscle tumour cell line confirmed the same finding through a different cannabinoid compound, with the apoptotic effect blocked when the CB1 receptor was specifically antagonised, confirming that the effect was receptor-mediated.
Why this matters for you, Corey: your tumour shares lineage and mechanisms with rhabdomyosarcoma, and the rhabdomyosarcoma literature is the most relevant adjacent body of evidence available. If the same CB1 upregulation is present in your tissue, then activating that receptor through ECS support is doing direct work at the cellular level, encouraging the right cells to undergo orderly death.
Oesch et al., 2009, Molecular Cancer Therapeutics. Cannabinoid receptor 1 is a potential drug target for translocation-positive rhabdomyosarcoma
Liu et al., 2020, Archives of Toxicology. Synthetic cannabinoid CP-55,940 induces apoptosis in a human skeletal muscle model via CB1 receptors and L-type Ca2+ channels
Beyond CB1, a range of cannabinoid pathways converge on tumour cell death through multiple distinct mechanisms. These have been studied across many tumour types, including soft tissue sarcomas, Ewing sarcoma, glioblastoma, colorectal cancer, breast cancer, and pancreatic cancer. The mechanisms include induction of endoplasmic reticulum stress, which triggers the unfolded protein response and forces tumour cells into either repair or programmed death; activation of autophagy, the cellular self-digestion process that, when dysregulated in tumour cells, drives them toward death; generation of ceramide, a lipid signalling molecule that sits upstream of multiple apoptosis pathways; cell cycle arrest in the G1 phase, which stops tumour cells from dividing; and inhibition of the same PI3K/Akt/mTOR survival pathway noted in Lever One.
The relevant point for you is that broad-spectrum ECS activation is not a single mechanism, it is a convergence of several distinct anti-tumour pathways running in parallel. That breadth of mechanism is part of why a sustained, twelve-month protocol can do work that a single-pathway intervention cannot.
Hinz and Ramer, 2019, British Journal of Pharmacology. Anti-tumour actions of cannabinoids
Seltzer et al., 2020, Cancers. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies
Peeri et al., 2024, Pharmaceuticals. Anti-Cancer and Anti-Proliferative Potential of Cannabidiol: A Cellular and Molecular Perspective
Inflammatory rhabdomyoblastic tumour is, by its very name and by its histology, an inflammation-driven disease. The dense inflammatory infiltrate is not incidental, it is part of what defines the tumour. That means any intervention that can quiet the inflammatory environment around the tumour is directly addressing one of the central features of the disease.
COX-2, cyclooxygenase-2, is a central enzyme in tumour-associated inflammation. It is also implicated in tumour cell migration, in metastasis, and in the maintenance of the inflammatory cycle that supports tumour growth. There are pharmaceutical COX-2 inhibitors, and they are used clinically, but they carry meaningful side effect profiles. Certain natural cannabinoid constituents have been shown to act as selective COX-2 inhibitors with high selectivity ratios and through different molecular mechanisms than the pharmaceuticals, including the downregulation of c-fos, a tumour-related transcription factor, and downregulation of Id-1, which is a positive regulator of metastasis.
In a tumour where inflammation and the potential for progression are the two things you most want to constrain, this is a mechanism with direct relevance.
Takeda et al., 2008, Drug Metabolism and Disposition. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis
Takeda et al., 2012, Toxicology Letters. CBDA, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
Takeda et al., 2014, Toxicology in Vitro. Down-regulation of cyclooxygenase-2 by CBDA in human breast cancer cells
The histiocytes that fill your tumour are tissue macrophages, and macrophages express CB2, the second cannabinoid receptor, in high density. CB2 is one of the master regulators of how macrophages behave. Macrophages can adopt different functional states, broadly characterised as M1, which is pro-inflammatory and tumour-attacking, and M2, which is pro-resolution and tissue-repairing but can also be tumour-permissive in cancer settings. ECS activation has been shown to influence this polarisation, with CB1 activation in particular pushing macrophages toward the M1 anti-tumour phenotype in cancer-specific studies, including increases in TNF-alpha and IL-6 release and decreases in the M2 markers IL-10, CD206, and Arg-1.
The honest framing for you is that the macrophage polarisation question in tumour biology is complex, and we do not have biopsy-confirmed data on the polarisation state of your specific infiltrate. The direction of the available evidence is supportive but the picture is nuanced. What is not in dispute is that the ECS is one of the central regulatory inputs to those cells, and that activating that system gives the body a regulatory lever over a cell population that is sitting right inside your tumour.
Deng et al., 2022, Cell Death Discovery. Cannabinoid Receptor-1 suppresses M2 macrophage polarization in colorectal cancer by downregulating EGFR
Turcotte et al., 2025, International Journal of Molecular Sciences. Cannabinoid Receptor 2 in Macrophages: A Promising Clinical Target for Immune Disorders
The studies in adjacent sarcoma types, including Ewing sarcoma, Kaposi sarcoma, and rhabdomyosarcoma, consistently show that these tumour cell lines express functional cannabinoid receptors and respond to receptor activation with reduced viability. This is not specific to your subtype, but it is a consistent pattern across the sarcoma family.
Soliman et al., 2022, Life Sciences. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
Your protocol is structured to do three things simultaneously. The sublingual tincture delivers a sustained, systemic cannabinoid signal that supports baseline ECS tone throughout the day. The suppository delivers a high-concentration dose into the rectal venous circulation, which bypasses first-pass liver metabolism and delivers substantially more of the active compounds into systemic circulation than oral routes can achieve. The transdermal topical delivers cannabinoid signal directly into the local tissue around your surgical scar and into the broader chest and rib cage area, which gives the body a localised concentration in the regions that matter most for your disease.
Together, these three routes activate the ECS systemically and locally, drive cannabinoid signalling through multiple receptors and through multiple cell death and inflammation pathways simultaneously, and do this on a sustained basis over the recommended twelve-month course. The slow-growth, indolent character of your tumour is precisely what allows a sustained intervention of this kind to potentially exert meaningful influence over a clinically relevant time window. This is not a two-week intervention, and your disease is not a two-week disease.
A minimum of four weeks is recommended before assessing how the body is responding to phytocannabinoid support. A full protocol course typically runs six to twelve months. The timeline below is a guide specific to this client's programme.
You are not walking this path alone. I stand beside you throughout this protocol, with full focus and commitment to your progress. Whether something shifts, a question arises, or you simply need guidance, reach out at any time. You do not need to wait for a scheduled call.
Your father Tom and I have been talking for months and I have wanted to speak with you for almost as long. You are in a strong position: physically capable, mentally engaged, asymptomatic, and trending in the right direction on imaging. That is the right window for this kind of protocol. Your discipline on the nutritional side is already there. The shift to confirmed therapeutic ketosis is a refinement, not a rebuild. Your relationship with physical activity is going to come back as the ECS activates and the topical does its job, and that matters to you, so we are going to plan around it.
This is a rare disease and I want to be honest with you that the disease-specific literature is thin. The broad mechanisms apply. The work I am going to do is to look much more deeply at the published material on inflammatory rhabdomyoblastic sarcoma and the cannabinoid mechanisms most likely to be relevant to it, and refine the suppository variant from my range of six if the research points that way. That research begins as soon as your records are in your Proton Drive folder. Upload the labs, the imaging, the histology, and the supplement list, and let us get to work. I am happy to speak with your Invita doctor whenever it is useful. We have the time. We are going to use it well.